Drug Trial Radar · NCT07951359
A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
345
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2029
Study completion Mar 2030
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
BNT3211Biological
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation periodTime frame: Up to 21 days from the initiation of first dose of BNT3211
- Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEsTime frame: From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
- Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEsTime frame: From the first until the last dose of BNT3211 (up to 36 months)
- Part B only - Objective response rateTime frame: Up to 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.